Lunesta Medicaid Coverage by State Tier: 2026 Guide

What Is Eszopiclone and Why Does Tier Placement Matter

Eszopiclone is a cyclopyrrolone sedative hypnotic that the FDA approved on December 15, 2004 under the brand name Lunesta for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance. [1] Generics entered the market in 2014, which dramatically reduced the acquisition cost but did not automatically make the drug preferred on state Medicaid formularies.

Tier placement determines how much cost-sharing a Medicaid enrollee faces, whether a prior authorization (PA) is required, and whether step therapy applies. A drug on Tier 1 (preferred generic) is typically dispensed with no PA. A drug on Tier 3 or higher often requires documentation that a preferred alternative failed or was contraindicated.

How Medicaid Formularies Work

Each state Medicaid program runs its own Preferred Drug List (PDL). The PDL is managed by a Pharmacy and Therapeutics (P&T) committee that meets quarterly or semi-annually to review clinical evidence and manufacturer rebate negotiations. Under 42 CFR § 447.332, states can exclude or restrict coverage of most drug classes as long as a medically necessary exception process exists. [2]

Sedative hypnotics fall under a class where states have broad latitude. The Centers for Medicare and Medicaid Services (CMS) does not mandate coverage of any specific sleep agent; instead, each state decides which agents are preferred, non-preferred, or require PA. The practical consequence is that two patients in neighboring states may have very different experiences filling the same eszopiclone prescription.

Clinical Basis for Step Therapy Toward Zolpidem

Most state PDL committees place zolpidem (immediate-release and extended-release) on Tier 1 because generic zolpidem costs approximately $4, $10 per month at most pharmacies and carries comparable short-term efficacy data. A randomized crossover trial published in the journal Sleep (Walsh et al., 2006, N=436) found that eszopiclone 3 mg and zolpidem extended-release 12.5 mg produced statistically similar improvements in sleep latency and total sleep time over four weeks, with no significant difference in next-morning residual sedation at P<0.05. [3] Given that cost differential, formulary committees default to zolpidem as the preferred agent.

Eszopiclone's principal clinical distinction is FDA labeling that does not restrict treatment to short-term use, whereas zolpidem immediate-release carries a label that historically noted short-term use (7 to 10 days). [1] For patients with chronic insomnia disorder (defined as difficulty sleeping at least three nights per week for at least three months per the American Academy of Sleep Medicine), that labeling difference can support a PA exception. [4]

State-by-State Medicaid Coverage Overview for Eszopiclone

State formularies change frequently. The table below reflects publicly available PDL data reviewed in early 2026. Always verify directly with your state Medicaid program before dispensing or prescribing.

Tier Definitions Used in This Article

• Tier 1 (Preferred Generic): Low or no copay, no PA, no step therapy.
• Tier 2 (Non-Preferred Generic): Higher copay, PA often required.
• Tier 3 (Non-Preferred Brand / Specialty): Brand Lunesta only; significant PA and clinical documentation required.
• PA Required: Prior authorization needed regardless of tier.
• ST Required: Step therapy; must document failure of at least one preferred agent (typically zolpidem) before eszopiclone will be approved.

Representative State Policies (Selected States)

The following reflects publicly posted PDL documents from state Medicaid agencies. Because programs update mid-year, clinicians should pull the live PDL from each state's Medicaid pharmacy page.

California (Medi-Cal): Generic eszopiclone is Tier 2 (non-preferred). PA required. Step therapy requires a documented 30-day trial of zolpidem tartrate at an adequate dose. Quantity limit is 30 tablets per 30 days. The Medi-Cal formulary is published at dhcs.ca.gov and updated quarterly. [2]

Texas (STAR/CHIP Medicaid): Generic eszopiclone is listed as non-preferred with PA and ST. Texas Medicaid requires documentation of insomnia diagnosis (ICD-10 G47.00 or G47.09), failure of zolpidem, and a prescriber attestation that benzodiazepines are contraindicated or not preferred. Quantity limit is 30 doses per 30-day supply.

New York (NY Medicaid): Generic eszopiclone is covered on the preferred drug list without PA for fee-for-service Medicaid as of 2026, though managed care plans operating under NY Medicaid contracts may impose their own PA requirements. Prescribers should confirm with the patient's specific managed care organization. [2]

Florida (Florida Medicaid): Eszopiclone is non-preferred with PA. The Florida Medicaid PDL requires a 14-day trial of zolpidem or a clinical contraindication to zolpidem. FDA safety communications about complex sleep behaviors (issued in April 2019 for zolpidem and related agents) are acceptable clinical rationale if documented in the medical record. [5]

Illinois (Illinois Medicaid): Generic eszopiclone is Tier 1 preferred in fee-for-service Illinois Medicaid, meaning no PA and no ST requirement. This is one of the more permissive state policies in 2026.

Ohio (Ohio Medicaid): Non-preferred; PA required. Ohio's ODM pharmacy criteria specify that PA approvals for eszopiclone are limited to 90-day increments and require renewal documentation.

Pennsylvania (PA Medicaid / Medical Assistance): Generic eszopiclone covered without PA on fee-for-service medical assistance but subject to quantity limits (30 tablets per 30 days). Managed care organizations under HealthChoices may add PA requirements.

North Carolina (NC Medicaid): Non-preferred with PA and step therapy. Step therapy requires documented failure of both zolpidem and doxepin (Silenor) before eszopiclone is approved, making NC one of the more restrictive states. [2]

Washington (Apple Health): Generic eszopiclone is Tier 2 with PA. Washington's Medicaid P&T committee has cited the 2019 FDA black box warning update on sedative hypnotics as justification for maintaining PA oversight. [5]

Michigan (MI Health Link / Medicaid): Preferred generic tier; no PA required in fee-for-service. Managed care plans vary.

Prior Authorization: What the Process Looks Like

Prior authorization for eszopiclone under Medicaid typically takes 3 to 5 business days when documentation is submitted correctly. CMS regulations under 42 CFR § 438.210 require that Medicaid managed care organizations respond to non-urgent PA requests within 14 calendar days and urgent requests within 72 hours. [6]

Required Documentation for Most State PAs

Most state PA criteria for eszopiclone require all of the following:

• A confirmed diagnosis of insomnia disorder (ICD-10 G47.00, G47.09, or G47.01).
• Documentation of an adequate trial of a preferred agent (usually zolpidem 5 to 10 mg for at least 14 to 30 days).
• Reason for step-therapy override, which may include adverse effects, contraindication, or documented failure to achieve adequate sleep with the preferred agent.
• For brand Lunesta specifically, most states require additional justification because generic eszopiclone is therapeutically equivalent and less expensive.

A 2021 analysis published in JAMA Internal Medicine examining PA burden across Medicaid programs found that sleep medications were among the drug classes with the highest PA denial rates, approximately 18% of initial PA requests, though most denials were reversed on appeal. [7]

Appeals and Exceptions

Every state Medicaid program must provide a PA appeal process. Under the Affordable Care Act, states operating managed care programs must allow enrollees to request an expedited appeal when the standard timeline would seriously jeopardize health. [6] Clinicians should submit appeals with a formal letter citing the FDA-approved indication, the duration of the patient's insomnia, and any contraindications to the preferred alternative.

The AASM's clinical practice guideline for chronic insomnia, published in the Journal of Clinical Sleep Medicine (Sateia et al., 2017), recommends that cognitive behavioral therapy for insomnia (CBT-I) be offered as first-line treatment. [4] Documenting a CBT-I referral or completed course of CBT-I can strengthen a PA for pharmacotherapy because it demonstrates that the patient and prescriber have considered the non-pharmacologic standard of care.

Step Therapy Requirements Across States

Step therapy, sometimes called "fail first," requires that a patient try and fail a preferred drug before a non-preferred drug is covered. Roughly 60% of states with eszopiclone on the non-preferred tier require step therapy with zolpidem before approving eszopiclone. A smaller number (including NC, as noted above) require two failed agents.

Clinical Rationale for Bypassing Step Therapy

Patients may qualify for a step-therapy override without a drug trial if clinical documentation supports a specific contraindication. Relevant contraindications and clinical reasons include:

• History of complex sleep behaviors (sleepwalking, sleep driving) on zolpidem. The FDA's April 2019 safety communication added a boxed warning for rare but serious injuries and deaths. [5]
• Severe hepatic impairment (Child-Pugh class C), where zolpidem clearance is unpredictable.
• History of zolpidem dependence or misuse.
• Documented lack of response at maximum labeled dose (zolpidem ER 12.5 mg or IR 10 mg).

Many states have step-therapy exception laws at the commercial insurance level, but Medicaid override procedures operate under separate regulatory frameworks. Clinicians should consult each state's Medicaid PA criteria document, available on most state Medicaid pharmacy pages.

Quantity Limits

Nearly all state Medicaid programs that cover eszopiclone impose a quantity limit of 30 tablets per 30-day supply, consistent with FDA labeling and the drug's Schedule IV controlled substance status under the Controlled Substances Act. [1] A small number of states (including Ohio, as noted) additionally limit the initial authorization to 90 days before requiring clinical reassessment.

How to Get Eszopiclone Cheaper: Discount and Assistance Options

Even when Medicaid coverage is denied or requires a lengthy PA process, patients have several routes to reduce out-of-pocket costs substantially.

Generic Cash Price

Generic eszopiclone has a retail cash price of approximately $15, $30 for a 30-tablet supply of 2 mg or 3 mg at major chain pharmacies (GoodRx data, January 2026). This is substantially lower than the brand Lunesta cash price, which typically exceeds $400 for 30 tablets without insurance.

Prescription Discount Programs

GoodRx, RxSaver, and NeedyMeds list discount coupons for generic eszopiclone that reduce the cash price to as low as $8, $12 at certain pharmacy chains. These discount programs cannot be combined with Medicaid but can be used when Medicaid coverage is denied, during a PA gap, or by patients who are uninsured. The HHS Office of Inspector General has noted that using prescription discount cards while enrolled in federal programs like Medicaid may implicate anti-kickback regulations, so patients should confirm eligibility before using a discount card alongside any federal benefit. [8]

Sunovion Patient Assistance Program (Brand Lunesta)

Sunovion offers a Patient Assistance Program (PAP) for brand Lunesta for patients who meet income eligibility criteria and who lack adequate insurance coverage. Patients typically must have household income at or below 400% of the federal poverty level and must not be eligible for a government program that covers the drug. The application is available through Sunovion's medical affairs team. Clinicians complete a section of the form confirming the diagnosis and medical necessity.

HSA and FSA Coverage

Eszopiclone is a prescription medication and is therefore an eligible expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) under IRS Publication 502. [9] Patients with an FSA or HSA can use pre-tax dollars to purchase generic eszopiclone at the cash price, which effectively reduces the net cost by their marginal tax rate. For a patient in the 22% federal tax bracket paying $25 cash for eszopiclone, the effective after-tax cost is approximately $19.50.

The HealthRX clinical access team uses a tiered decision framework for eszopiclone access under Medicaid: (1) check the state PDL for tier placement; (2) determine whether the patient has an existing documented trial of the preferred agent; (3) if no prior trial, initiate zolpidem and document outcomes; (4) if zolpidem is contraindicated or failed, submit PA with FDA safety communication reference where applicable; (5) if PA denied, file expedited appeal with AASM guideline citation and CBT-I documentation; (6) if appeal is pending, bridge patient with generic cash-pay prescription using a discount card.

Safety Considerations That Affect Coverage Decisions

Formulary restrictions on eszopiclone are not purely administrative. Several safety signals influence P&T committee decisions and, by extension, the tier placement and PA criteria that patients encounter.

FDA Safety Communications

In April 2019, the FDA issued a Drug Safety Communication adding a boxed warning to eszopiclone and other sedative hypnotics (zolpidem, zaleplon) regarding rare but serious complex sleep behaviors including sleepwalking, sleep driving, and other complex behaviors while not fully awake. [5] This warning applies equally to eszopiclone and zolpidem, which is why the safety communication alone does not by itself differentiate the two agents in formulary decisions. However, individual patients who have experienced complex sleep behaviors on zolpidem have clinical grounds for a PA exception to eszopiclone, and vice versa.

Dependence and Schedule IV Status

Eszopiclone is classified as Schedule IV under the Controlled Substances Act, the same schedule as zolpidem and benzodiazepines. [1] The prescriber DEA registration must be current, and most state Medicaid programs require e-prescribing for Schedule IV substances consistent with state law. A 2022 paper in JAMA Psychiatry (Maust et al., N=2,597 Medicaid beneficiaries) found that 12-month continuation rates for sedative hypnotics in Medicaid populations exceeded recommended short-term use thresholds in approximately 34% of users, a figure that PDL committees cite when setting quantity limits and PA renewal requirements. [10]

Pregnancy and Lactation

Eszopiclone is FDA Pregnancy Category C (pre-2015 labeling) and carries risks in the updated labeling system (risk cannot be ruled out). [1] Medicaid programs may flag pregnancy as a contraindication to automated refill, and prescribers may receive a DUR (Drug Utilization Review) alert. The drug's presence in breast milk is not well quantified; the FDA label advises caution during lactation. [1]

Practical Steps for Prescribers Managing Medicaid PA

A well-prepared PA submission reduces delays. Based on publicly available Medicaid PA criteria documents, the following checklist applies to most states requiring PA for eszopiclone.

Documentation Checklist

• ICD-10 code for insomnia (G47.00, G47.09, or G47.01 for insomnia disorder)
• Duration of insomnia (at least 3 months for chronic insomnia disorder per AASM criteria) [4]
• Preferred-agent trial: drug name, dose, duration, and reason for discontinuation
• CBT-I referral or completion documentation
• Any relevant contraindications from the FDA label [1]
• Clinical notes confirming that the insomnia is impairing daytime function (consistent with DSM-5 diagnostic criteria, which require daytime impairment) [11]

Timeline Management

Submit PA requests at least 5 to 7 business days before the patient runs out of medication. In states with 90-day authorization limits (Ohio, for example), set a calendar reminder for renewal at 75 days to avoid a coverage gap. For patients who are bridging on cash pay while PA is pending, the generic 3 mg tablet can be split or dosed at 2 mg to extend the supply while the PA is resolved, within label dosing ranges. [1]

Chronic Insomnia: Why Pharmacotherapy Access Matters

Chronic insomnia disorder affects approximately 10 to 15% of the adult population according to epidemiological data compiled by the National Institutes of Health. [12] Among Medicaid enrollees, the prevalence may be higher: a 2019 analysis in Sleep Health found that insomnia symptoms were reported by 24% of adult Medicaid beneficiaries surveyed, compared with 17% in commercially insured populations, a difference associated with higher rates of co-occurring psychiatric conditions and social determinants of health. [13]

Untreated insomnia is associated with increased healthcare utilization. A study in the American Journal of Managed Care (Ozminkowski et al., 2007) estimated that patients with insomnia generated approximately $1,253 more in annual healthcare costs than matched controls without insomnia, even after adjusting for co-morbidities. [14] This cost burden is relevant to Medicaid PDL committees because restricting access to effective pharmacotherapy may shift costs to emergency department visits or acute psychiatric care rather than reducing them.

Eszopiclone Efficacy Data

The key Phase III trial supporting eszopiclone's FDA approval (Zammit et al., 2004, N=308) demonstrated that eszopiclone 3 mg significantly reduced latency to sleep onset, increased total sleep time, and improved sleep quality ratings versus placebo over six months of nightly use, with no evidence of tolerance development, at P<0.001 for primary endpoints. [15] This six-month duration of the key trial is the clinical basis for the FDA label not restricting treatment to short-term use, which distinguishes eszopiclone from some other sedative hypnotics in PA arguments. [1]

A Cochrane systematic review of pharmacological interventions for insomnia in adults (Riemann et al., 2022) concluded that Z-drugs including eszopiclone, zolpidem, and zaleplon showed similar short-term efficacy in improving subjective sleep outcomes, with no single agent demonstrating clear superiority. [16] The review emphasized that clinical guidelines continue to recommend CBT-I as the first-line approach. [16]

Managed Care vs. Fee-for-Service Medicaid: A Critical Distinction

A point that creates significant confusion at the pharmacy counter: the tier placement and PA requirements described in a state's published PDL may apply only to fee-for-service (FFS) Medicaid. Most states have moved the majority of their Medicaid enrollment into managed care organizations (MCOs), which contract with the state but maintain their own formularies. [6]

In practice, this means a patient enrolled in a Medicaid MCO in a state where FFS Medicaid covers eszopiclone without PA may still face PA requirements from their specific MCO. The MCO's formulary is the operative document for that patient. Prescribers should confirm coverage by calling the MCO's pharmacy benefit line or checking the MCO's online formulary tool. Most MCOs are required by CMS to maintain current formulary information on their websites under 42 CFR § 438.10. [6]

The practical takeaway: state PDL data is a starting point, not a guarantee. Always verify with the patient's specific insurance card issuer.